[go: up one dir, main page]

WO1997010823A1 - Antagonistes du recepteur de 5-ht3 contre la dyskinesie - Google Patents

Antagonistes du recepteur de 5-ht3 contre la dyskinesie Download PDF

Info

Publication number
WO1997010823A1
WO1997010823A1 PCT/CA1996/000616 CA9600616W WO9710823A1 WO 1997010823 A1 WO1997010823 A1 WO 1997010823A1 CA 9600616 W CA9600616 W CA 9600616W WO 9710823 A1 WO9710823 A1 WO 9710823A1
Authority
WO
WIPO (PCT)
Prior art keywords
tremor
dyskinesia
pharmaceutically acceptable
treatment
ondansetron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1996/000616
Other languages
English (en)
Inventor
George Peter Arthur Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
SmithKline Beecham Corp
Original Assignee
Glaxo Group Ltd
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519029.4A external-priority patent/GB9519029D0/en
Priority claimed from GBGB9519021.1A external-priority patent/GB9519021D0/en
Priority to DE69625819T priority Critical patent/DE69625819T2/de
Priority to CA002231887A priority patent/CA2231887A1/fr
Priority to EP96929991A priority patent/EP0851756B1/fr
Priority to IL12353696A priority patent/IL123536A0/xx
Priority to PL96325560A priority patent/PL325560A1/xx
Priority to AT96929991T priority patent/ATE230988T1/de
Application filed by Glaxo Group Ltd, Glaxo Wellcome Inc filed Critical Glaxo Group Ltd
Priority to AU69211/96A priority patent/AU6921196A/en
Priority to HU9900606A priority patent/HUP9900606A2/hu
Priority to JP51226097A priority patent/JP3411292B2/ja
Priority to BR9610526A priority patent/BR9610526A/pt
Priority to EA199800204A priority patent/EA199800204A1/ru
Publication of WO1997010823A1 publication Critical patent/WO1997010823A1/fr
Priority to IS4686A priority patent/IS4686A/is
Priority to NO981188A priority patent/NO981188L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Definitions

  • the invention relates to a new medical use for compounds which act as antagonists of 5-hydroxytryptam ⁇ ne (5-HT) at 5-HT 3 receptors
  • 5_HT 3 receptor antagonists may be identified by methods well known in the art, for example by their ability to inhibit 3-(5-methyl-1 H- ⁇ rn ⁇ dazole-4-yl)-1-[1-[ 3 H]- methyl-1 H- ⁇ ndol-3-yl]-1-propanone binding in rat entorhinal cortex homogenates (following the general procedure described by G Kilpatnck et al, Nature, 1987, 330, 746-748), and/or by their effect on the 5-HT- ⁇ nduced Bezold-Jansch (B-J) reflex in the cat (following the general method described by A Butler et al, Br J Pharmacol , 94, 397-412 (1988))
  • Particular examples of compounds from within Group A include the compounds of Group B, namely:
  • (dolasetron) preferably in the form of its mesilate; endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- 7-benzofuran carboxamide (zatosetron);
  • Suitable 5-HT 3 receptor antagonists for use according to the invention include the compounds of Group C, namely:
  • (+)-endo-4-(propionyloxy)-6-(4-fluorophenyl)-1 -azabicyclo(3.3.1 )non-6-ene hydrochloride (GYKI-46903); and 3-(2-(4'-piperonylpiperazinyl)indol)carboxyaldehyde (VA-21 B7).
  • 5-HT 3 receptor antagonists are known to be useful in the treatment of a variety of conditions involving 5-HT 3 receptor-mediated mechanisms, including in particular emesis.
  • Abnormal involuntary movements or dyskinesias include, inter alia, tremor, chorea, myoclonus and tics. In addition to these categories of dyskinesia, there is a particular set of involuntary movements known as tardive dyskinesia or drug-induced tardive dyskinesia.
  • Tremor is an abnormal involuntary trembling or quivering. It may be characterised as a rhythmic sinusoidal movement of a body part caused by regular rhythmic muscle contractions.
  • Chorea consists of a continuous flow of irregular, jerky, and explosive movements, that flit from one portion of the body to another in random sequence. Each muscle contraction is brief, often appearing as a fragment of what might have been a normal movement, and quite unpredictable in timing or site.
  • Myoclonus consists of rapid shock-like muscle jerks, often repetitive and sometimes rhythmic.
  • Tics are similar to myoclonic jerks in appearance, but are repetitive, stereotyped movements that can be mimicked voluntarily and can be held in check by an effort of will at the expense of mounting inner tension.
  • Tardive dyskinesia is typically marked by involuntary repetitive movements of the facial, buccal, oral and cervical musculature
  • dyskinesia in particular where dyskinesia is the solitary feature of the illness (e.g. benign essential (familial) tremor and benign essential (myoclonus)), include alcohol; benzodiazepi ⁇ es, such as diazepam, lorazepam and clonazepam; and ⁇ -adrenergic receptor antagonists, such as propranolol.
  • Other dyskinesias are often a facet of another neurological disease and treatment of the dyskinesia follows that appropriate for the relevant neurological disease.
  • the treatment of tremor caused by Parkinson's disease may be by dopaminergic agents such as levodapa and antimuscarinic agents such as benzhexol.
  • 5-HT 3 receptor antagonists are also of use in the treatment of dyskinesia.
  • the invention therefore provides a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of dyskinesia.
  • pharmaceutically acceptable derivative any pharmaceutically acceptable salt or solvate of a 5-HT 3 receptor antagonist or any other compound, which upon administration to the recipient is capable of providing (directly or indirectly) a 5-HT 3 receptor antagonist or an active metabolite or residue thereof.
  • the invention provides a compound of Group A or a pharmaceutically acceptable derivative thereof, more preferably a compound of Group B or a pharmaceutically acceptable derivative thereof, for use in the treatment of dyskinesia.
  • the invention therefore provides ondansetron or a pharmaceutically acceptable derivative thereof for use in the treatment of dyskinesia.
  • Suitable pharmaceutically acceptable salts of ondansetron include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p-toluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, salicylates, succinates, lactates, glutarates, glutaconates, acetates, tricarballylates, citrates, fumarates and maleates), and solvates (for example hydrates) thereof.
  • ondansetron is employed in the form of its hydrochloride, more preferably its hydrochloride dihydrate.
  • ondansetron is employed in the form of its free base.
  • ondansetron contains one chiral centre (shown by * in the formula (I)) and that ondansetron therefore exists in the form of optical isomers (i.e. enantiomers).
  • the invention includes all isomers of ondansetron and its pharmaceutically acceptable derivatives, including all tautomeric and optical forms, and mixtures thereof, including racemic mixtures.
  • Each type of dyskinesia may be caused by a variety of diseases. It may be accompanied by other neurological deficits or the abnormal involuntary movements may occur in isolation and constitute the illness.
  • 5-HT 3 receptor antagonists are in particular useful in the treatment of tremor, chorea, myoclonus, tics, and tardive dyskinesia.
  • Tremor includes rest tremor, postural tremor and intention tremor.
  • Rest tremor may be caused by, for example, Parkinson's disease, post-encephalitic Parkinsonism, drug-induced Parkinsonism and other extrapyramidal diseases.
  • Postural tremor may be caused by, for example, physiological tremor; exaggerated physiological tremor attributable to, for example, thyrotoxicosis, anxiety states, alcohol, drugs (such as, sy pathomimetics, anti-depressants and lithium) and heavy metal poisoning (such as mercury); hyperthyroidism, structural brain disease attributable to, for example, severe cerebellar lesions, Wilson's disease and neurosyphilis; and benign essential (familial) tremor.
  • Intention tremor may be caused by, for example, brain stem or cerebellar disease attributable to, for example, multiple sclerosis (MS), spinocerebellar degenerations, vascular disease and tumour.
  • MS multiple sclerosis
  • Chorea includes Sydenham's chorea, Huntington's disease, benign hereditary chorea, symptomatic chorea, drug-induced chorea and hemiballism (hemichorea).
  • Myoclonus includes generalised myoclonus, such as progressive myoclonic encephalopathies, static myoclonic encephalopathies, myoclonic epilepsies, benign essential (familial) myoclonus and focal myoclonus (segmental).
  • Tics include simple tics, complex multiple tics (e.g. Gilles de la Tourette syndrome) and symptomatic tics.
  • Tardive dyskinesia may develop following the treatment of, for example, psychotic disorders (such as schizophrenia and mania) with neuroleptics, such as phenothiazines; and cognitive disorders such as dementia (e.g. Parkinson's disease), with dopaminergic agents, such as levodopa. Tardive dyskinesia may persist after withdrawal of the treatment.
  • psychotic disorders such as schizophrenia and mania
  • neuroleptics such as phenothiazines
  • cognitive disorders such as dementia (e.g. Parkinson's disease)
  • dopaminergic agents such as levodopa.
  • Tardive dyskinesia may persist after withdrawal of the treatment.
  • the invention provides a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of tremor.
  • the invention provides a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of benign essential (familial) tremor.
  • Benign essential (familial) tremor may present at any age and is often inherited as an autosomal dominant trait. It is characterised by postural tremor of the arms and head, although the jaw, tongue, legs and trunk may also be affected.
  • the invention provides a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of intention tremor.
  • the invention provides a method of treatment of a mammal, including man, suffering from dyskinesia which comprises administering an effective amount of a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof.
  • the invention provides the use of a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of dyskinesia.
  • a 5-HT 3 receptor antagonist of Group A more preferably a 5-HT 3 receptor antagonist of Group B, most preferably ondansetron, is especially preferred.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may, for example, be formulated for oral, sub-lingual, buccal, parenteral, rectal or intranasal administration, or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose), or in a form suitable for topical administration.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrates (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrates e.g. potato starch or sodium starch glycollate
  • wetting agents
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl-f hydroxybenzoates or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles e.g. almond oil, oily esters or ethyl alcohol
  • preservatives e.g
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may be formulated for parenteral administration by injection, conveniently intravenous, intramuscular or subcutaneous injection, for example by bolus injection or continuous intravenous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, optionally with an added preservative.
  • compositions for parenteral administration may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the compositions may be in dry form such as a powder, crystalline or freeze-dried solid for constitution with a suitable vehicle, e.g. sterile pyrogen-free water or isotonic saline before use. They may be presented, for example, in sterile ampoules or vials.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may also be formulated in rectal compositions such as suppositories or retention enemas.
  • Tablets for sub-lingual administration may be formulated in a conventional manner.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may be formulated in a conventional manner.
  • compositions may be liquids, for example solutions, suspensions or emulsions presented in the form of creams or gels.
  • a 5-HT 3 receptor antagonist or a pharmaceutically acceptable derivative thereof may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection.
  • the compositions may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Pharmaceutical formulations of ondansetron or a pharmaceutically acceptable derivative thereof may be prepared, for example, according to UK Patent No. GB 2153821 B, European Patent Application Publication No. 276559 or International Patent Application Publication Nos. WO94/27599, WO96/15785 or WO96/15786.
  • a 5-HT 3 receptor antagonist expressed in the form of its free base, will depend on the age and condition of the patient and the nature of the dyskinesia to be treated, and will be at the ultimate discretion of the attendant physician.
  • effective doses for the treatment of dyskinesia in particular, tremor will lie in the range of 0.001 to 500mg, such as 0.01 to 100mg, preferably 0.05 to 50mg, for example 0.5 to 25mg per unit dose, which could be administered in single or divided doses, for example, 1 to 4 times per day.
  • effective doses of ondansetron for the treatment of tremor will lie in the range of 0.05 to 100mg, such as 0.1 to 50mg, preferably 0.5 to 25mg, for example 2, 4, 8 or 16mg of ondansetron per unit dose, which could be administered in single or divided doses, for example, 1 to 4 times per day.
  • ondansetron in the treatment of dyskinesia is supported by the following clinical data.
  • the clinical outcome was measured at baseline and one hour following the infusion.
  • Figures 1 (a), (b) and (c) represent an attempt to copy a spiral by the first mentioned patient in Table 1.
  • Figure 1(a) represents an attempt prior to treatment with ondansetron; figure 1 (b) an attempt after receiving placebo; and figure 1 (c) an attempt after receiving ondansetron.
  • Cd Cerebellar degeneration.
  • Ondansetron was well tolerated and the effect could be sustained in the long term. Withdrawal of the medication resulted in the tremor returning to pre-study levels. None worked well for the tremor in these patients prior to the use of ondansetron.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

Utilisation d'un antagoniste du récepteur de 5-HT3 ou d'un dérivé pharmaceutiquement acceptable de celui-ci dans le traitement de la dyskinésie.
PCT/CA1996/000616 1995-09-18 1996-09-16 Antagonistes du recepteur de 5-ht3 contre la dyskinesie Ceased WO1997010823A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR9610526A BR9610526A (pt) 1995-09-18 1996-09-16 Uso de um antagonista receptor de 5-HT3 ou um seu derivado farmaceuticamente aceitável processo de tratamento de um mamífero incluindo o homem que esteja sofrendo de discinesia e o referido antagonista
EA199800204A EA199800204A1 (ru) 1995-09-18 1996-09-16 Антагонисты 5-нтрецепторов для лечения дискинезии
JP51226097A JP3411292B2 (ja) 1995-09-18 1996-09-16 ジスキネジー用５−ｈｔ３レセプターアンタゴニスト
EP96929991A EP0851756B1 (fr) 1995-09-18 1996-09-16 Utilisation d' ondansetron pour la fabrication d' une medicament pour le traitment de tremulation
IL12353696A IL123536A0 (en) 1995-09-18 1996-09-16 5-HT3 Receptor antagonists for dyskinesia
PL96325560A PL325560A1 (en) 1995-09-18 1996-09-16 Inhibitors of 5-ht 3 receptors in treating diskinesis
AT96929991T ATE230988T1 (de) 1995-09-18 1996-09-16 Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
DE69625819T DE69625819T2 (de) 1995-09-18 1996-09-16 Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
AU69211/96A AU6921196A (en) 1995-09-18 1996-09-16 5-ht3 receptor antagonists for dyskinesia
HU9900606A HUP9900606A2 (hu) 1995-09-18 1996-09-16 5-HT3 Receptor antagonisták mozgászavar kezelésére
CA002231887A CA2231887A1 (fr) 1995-09-18 1996-09-16 Antagonistes du recepteur de 5-ht3 contre la dyskinesie
IS4686A IS4686A (is) 1995-09-18 1998-03-09 5-HT3 viðtaka mótefni fyrir hreyfibilun
NO981188A NO981188L (no) 1995-09-18 1998-03-17 5-HT3-reseptorantagonister for dyskinesi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9519021.1 1995-09-18
GBGB9519029.4A GB9519029D0 (en) 1995-09-18 1995-09-18 Medicaments
GBGB9519021.1A GB9519021D0 (en) 1995-09-18 1995-09-18 Medicaments
GB9519029.4 1995-09-18

Publications (1)

Publication Number Publication Date
WO1997010823A1 true WO1997010823A1 (fr) 1997-03-27

Family

ID=26307778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1996/000616 Ceased WO1997010823A1 (fr) 1995-09-18 1996-09-16 Antagonistes du recepteur de 5-ht3 contre la dyskinesie

Country Status (19)

Country Link
EP (1) EP0851756B1 (fr)
JP (1) JP3411292B2 (fr)
KR (1) KR19990045728A (fr)
CN (1) CN1201390A (fr)
AT (1) ATE230988T1 (fr)
AU (1) AU6921196A (fr)
BR (1) BR9610526A (fr)
CA (1) CA2231887A1 (fr)
CZ (1) CZ82698A3 (fr)
DE (1) DE69625819T2 (fr)
EA (1) EA199800204A1 (fr)
ES (1) ES2191106T3 (fr)
HU (1) HUP9900606A2 (fr)
IL (1) IL123536A0 (fr)
IS (1) IS4686A (fr)
NO (1) NO981188L (fr)
PL (1) PL325560A1 (fr)
TR (1) TR199800488T1 (fr)
WO (1) WO1997010823A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (fr) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Moyens et methodes de traitement ameliores utilisant des 'setrones'

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337547A1 (fr) * 1988-04-11 1989-10-18 Merck Sharp & Dohme Ltd. Composés spirocycliques avec cycles à 5 chaînons à deux hétéroatomes
GB2229182A (en) * 1989-03-14 1990-09-19 Merck Sharp & Dohme Five-membered ring systems with bonded imidazolyl ring substituents
EP0407137A2 (fr) * 1989-07-03 1991-01-09 Yoshitomi Pharmaceutical Industries, Ltd. Dérivés de benzazine et leurs applications pharmaceutiques
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
FR2693194A1 (fr) * 1992-07-03 1994-01-07 Synthelabo Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique.
EP0591027A1 (fr) * 1992-09-28 1994-04-06 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
EP0646583A1 (fr) * 1993-10-04 1995-04-05 Synthelabo Dérivés d'imidazol-4-yl-pipéridine, leur préparation et leur application en thérapeutique
EP0732334A1 (fr) * 1995-03-13 1996-09-18 Synthelabo Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337547A1 (fr) * 1988-04-11 1989-10-18 Merck Sharp & Dohme Ltd. Composés spirocycliques avec cycles à 5 chaînons à deux hétéroatomes
GB2229182A (en) * 1989-03-14 1990-09-19 Merck Sharp & Dohme Five-membered ring systems with bonded imidazolyl ring substituents
EP0407137A2 (fr) * 1989-07-03 1991-01-09 Yoshitomi Pharmaceutical Industries, Ltd. Dérivés de benzazine et leurs applications pharmaceutiques
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
FR2693194A1 (fr) * 1992-07-03 1994-01-07 Synthelabo Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique.
EP0591027A1 (fr) * 1992-09-28 1994-04-06 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
EP0646583A1 (fr) * 1993-10-04 1995-04-05 Synthelabo Dérivés d'imidazol-4-yl-pipéridine, leur préparation et leur application en thérapeutique
EP0732334A1 (fr) * 1995-03-13 1996-09-18 Synthelabo Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DIALOG INFORMATION SERVICES, FILE 73: EMBASE, ACCESSION NUMBER 6436035, XP002024612 *
G.P.A.RICE ET AL.: "Ondansetron for intractable vertigo complicating acute brainstem disorders", LANCET, vol. 345, 6 May 1995 (1995-05-06), pages 1182 - 1183, XP000644332 *
G.RICE ET AL.: "Ondansetron for Disabling Cerebellar Tremor", ANN.NEUROL., vol. 38, no. 6, December 1995 (1995-12-01), pages 973, XP000644312 *
G.T.SHEARMAN ET AL.: "Effect of the selective 5-HTsub 3 receptor antagonists ICS 205-930 and MDL 72222 on 5-HTP-induced head shaking and behavioral symptoms induced by 5-methoxy-N,N,dimethyltryptamine in rats: Comparison with some other 5-HT receptor antagonists", PSYCHOPHARMACOLOGY, vol. 92, no. 4, 1987, pages 520 - 523 *
H.NISSBRANDT ET AL.: "The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 346, no. 1, 1992, pages 12 - 19, XP000616538 *
K.A.YOUNG ET AL.: "Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment", J.NEURAL.TRANSM.GEN.SECT., vol. 86, no. 3, 1991, pages 223 - 228, XP000616560 *
S.K.YEGHIAYAN ET AL: "Serotonergic Stimulation of the Ventrolateral Striatum Induces Orofacial Stereotypy", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 52, no. 3, 1995, pages 493 - 501, XP000616549 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (fr) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Moyens et methodes de traitement ameliores utilisant des 'setrones'

Also Published As

Publication number Publication date
JP3411292B2 (ja) 2003-05-26
DE69625819D1 (de) 2003-02-20
TR199800488T1 (xx) 1998-05-21
EP0851756B1 (fr) 2003-01-15
MX9802001A (es) 1998-10-31
NO981188D0 (no) 1998-03-17
IS4686A (is) 1998-03-09
CA2231887A1 (fr) 1997-03-27
PL325560A1 (en) 1998-08-03
AU6921196A (en) 1997-04-09
EP0851756A1 (fr) 1998-07-08
ES2191106T3 (es) 2003-09-01
IL123536A0 (en) 1998-10-30
HUP9900606A2 (hu) 2000-03-28
CN1201390A (zh) 1998-12-09
NO981188L (no) 1998-05-13
JPH10511986A (ja) 1998-11-17
DE69625819T2 (de) 2003-11-06
ATE230988T1 (de) 2003-02-15
BR9610526A (pt) 1999-07-06
CZ82698A3 (cs) 1998-08-12
KR19990045728A (ko) 1999-06-25
EA199800204A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
RU2165760C2 (ru) Применение антагонистов серотонина (5нт3) для лечения фибромиалгии
US5225407A (en) 5-HT3 receptor antagonists for the treatment of autism
US10548855B2 (en) Memantine combinations and use
JP6050115B2 (ja) アルツハイマー型認知症を治療するための方法及び組成物
AU3768001A (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP2022502479A (ja) パーキンソン病および関連疾患の治療のための組成物および使用
WO2001095903A1 (fr) Antagonistes du recepteur 5-ht3 destines au traitement de troubles englobant la constriction des voies aeriennes
WO2001095902A9 (fr) Composition contenant une association d'agonistes et d'antagonistes d'un recepteur
WO2002036113A1 (fr) Composition comprenant des agonistes (5ht-4) et des antagonistes (5ht-2, 5ht-3) recepteurs de la serotonine
WO2002036114A1 (fr) Composition comprenant les antagonistes des recepteurs de serotonine 5 ht-2 et 5 ht-3
JPH0648960A (ja) 医 薬
WO2012002583A1 (fr) Procédé de traitement de la schizophrénie et de maladies apparentées au moyen d'une polythérapie
EP0851756B1 (fr) Utilisation d' ondansetron pour la fabrication d' une medicament pour le traitment de tremulation
US5530008A (en) Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
MXPA98002001A (en) Antagonists of receiver 5-th3 for discine
KR100829297B1 (ko) 2-아릴-8-옥소디히드로푸린 유도체를 유효성분으로 하는치매증 치료제
JPWO2003018012A1 (ja) 便秘型ｉｂｓ予防剤／治療剤
WO2005094797A2 (fr) Nouveaux antagonistes de recepteur ampa

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96198141.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

ENP Entry into the national phase

Ref document number: 1997 836053

Country of ref document: US

Date of ref document: 19970514

Kind code of ref document: A

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 316869

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2231887

Country of ref document: CA

Ref document number: 2231887

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/002001

Country of ref document: MX

Ref document number: 199800204

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1996929991

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019980701969

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1998-826

Country of ref document: CZ

Ref document number: 1998/00488

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1996929991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-826

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1998-826

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980701969

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980701969

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996929991

Country of ref document: EP